InsiderClue
← All stocks

Edgewise Therapeutics, Inc.

EWTX Net buying
CIK 0001710072 #1406 in the set updated 18 Sep 2026
Bought (120 mo)
$79.04M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$46.45M
$506.73K on a plan · $38.09M straight out of an exercise
Sold at will
$7.86M
60 of 145 sales
Net
+$32.59M
+$71.18M against sales at will

By person

15 insiders · 172 transactions
Insider
Role
Bought
Sold
Net
Holding
Of company
Worth
Change
ORBIMED ADVISORS LLC entity
Director
$26.74M (7)
—
+$26.74M
443,792
0.4086%
$19.26M
—
Thompson Peter A.
Director
$26.74M (7)
—
+$26.74M
443,792
0.4086%
$19.26M
—
Russell Alan J
Chief Scientific Officer
—
$23.50M (54) scheduled
−$23.50M
31,466
0.0290%
$1.37M
−88.5%
Novo Holdings A/S entity
10% owner
$15.00M (2)
—
+$15.00M
6,071,703
5.59%
$263.55M
—
Flynn James E
10% owner
$10.00M (1)
—
+$10.00M
3,933,137
3.62%
$170.72M
—
Donovan Joanne M.
CMO
—
$5.74M (17) scheduled
−$5.74M
8,625
0.0079%
$374.38K
−27.9%
Carruthers R Michael
Chief Financial Officer
—
$5.09M (9) scheduled
−$5.09M
86,162
0.0793%
$3.74M
+682.2%
MOORE JOHN R
General Counsel
—
$4.45M (35) scheduled
−$4.45M
17,697
0.0163%
$768.16K
+241.2%
Edris Badreddin
Director
—
$3.40M (5) scheduled
−$3.40M
19,820
0.0182%
$860.32K
0.0%
Derakhshan Behrad
Chief Business Officer
—
$2.05M (13) scheduled
−$2.05M
31,826
0.0293%
$1.38M
+221.9%
KOCH KEVIN
President and CEO
—
$1.34M (10) scheduled
−$1.34M
52,488
0.0483%
$2.28M
—
Semigran Marc
Chief Development Officer
—
$881.92K (2) scheduled
−$881.92K
6,716
0.0062%
$291.52K
0.0%
Fox Jonathan C
Director
$300.36K (2)
—
+$300.36K
24,833
0.0229%
$1.08M
—
ROOT JONATHAN D
Director
$250.00K (1)
—
+$250.00K
15,625
0.0144%
$678.23K
—
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.
10% owner
—
—
—
681,812
0.6278%
$29.60M
—

Individual transactions

20
Insider
Date
Role
Action
Shares
Price
Amount
Fox Jonathan C
11 Nov 2025
Director
Buy
10,700
$18.64
$199.40K
ORBIMED ADVISORS LLC
3 Apr 2025
Director
Buy indirect
124,193
$20.13
$2.50M
ORBIMED ADVISORS LLC
3 Apr 2025
Director
Buy indirect
372,578
$20.13
$7.50M
Thompson Peter A.
3 Apr 2025
Director
Buy indirect
124,193
$20.13
$2.50M
Thompson Peter A.
3 Apr 2025
Director
Buy indirect
372,578
$20.13
$7.50M
ORBIMED ADVISORS LLC
23 Jan 2024
Director
Buy indirect
454,545
$11.00
$5.00M
Thompson Peter A.
23 Jan 2024
Director
Buy indirect
454,545
$11.00
$5.00M
Fox Jonathan C
26 Dec 2023
Director
Buy
10,857
$9.30
$100.96K
ORBIMED ADVISORS LLC
16 Sep 2022
Director
Buy indirect
484,496
$10.32
$5.00M
Thompson Peter A.
16 Sep 2022
Director
Buy indirect
484,496
$10.32
$5.00M
Novo Holdings A/S
14 Sep 2022
10% owner
Buy
484,496
$10.32
$5.00M
Thompson Peter A.
18 May 2022
Director
Buy indirect
138,000
$7.21
$994.98K
ORBIMED ADVISORS LLC
18 May 2022
Director
Buy indirect
138,000
$7.21
$994.98K
Flynn James E
30 Mar 2021
10% owner
Buy indirect
625,000
$16.00
$10.00M
Novo Holdings A/S
30 Mar 2021
10% owner
Buy
625,000
$16.00
$10.00M
ORBIMED ADVISORS LLC
30 Mar 2021
Director
Buy indirect
312,500
$16.00
$5.00M
ORBIMED ADVISORS LLC
30 Mar 2021
Director
Buy indirect
46,875
$16.00
$750.00K
Thompson Peter A.
30 Mar 2021
Director
Buy indirect
312,500
$16.00
$5.00M
Thompson Peter A.
30 Mar 2021
Director
Buy indirect
46,875
$16.00
$750.00K
ROOT JONATHAN D
30 Mar 2021
Director
Buy
15,625
$16.00
$250.00K
Show all 172 transactions →

What was left out

Form 4 filings counted 173
Amendments (4/A) skipped 5
Filings about a different issuer 0
Unreadable filings 0
Joint filings 6
Sales on a Rule 10b5-1 plan 2
Sales straight out of an exercise 83
Sales at will 60
Transactions with no price 0
Shares from compensation/vesting 43,853,493
Sales filed before the plan box existed 37
History held since 30 Mar 2021